I love these parts down towards the bottom. Thanks
Post# of 30028
Posted On: 01/06/2015 2:35:08 AM
I love these parts down towards the bottom. Thanks for pulling this back up to the front of my mind Maui!
Like I've stated before, I wouldn't be surprised if Lympro will be able to distinguish between AD or other cognitive impairments/dementia's whether do to age, menopause or even PMS for that matter! All kidding aside, I hope this will be the cherry on top. One test using different algorithms to see what one really has going on upstairs.
"Of note, when we compared only the Alzheimer’s and cognitively intact groups, we had an accuracy of 90% in this small data set. In the upcoming Bridging Study, we will be comparing only Alzheimer’s and cognitively intact controls in order to give us a true clean measure of Version 1 vs. Version 2 using analytically strong data from BD. We believe this step will give us all the tools necessary to support the transition of the assay from BD into the target commercial CLIA lab partner and then restart the work PLS had conducted, and add other dementias into the cohort group (distinguishing Alzheimer’s from other dementias and cognitively intact controls using biomarkers such as Amyvid)."
"Some may ask, “How will you get another clinical study completed by the end of the year in the CLIA lab, as is required to support submission?” The answer is that we are proving right now that we can execute under such timelines with the current study. This is where the relationships and expertise and experiences of Dr. Kirby’s over 400 clinical trials are a huge advantage for Amarantus. We are establishing a well-oiled clinical organization capable of translating protocols to practice, and ultimately to data at a very rapid pace."
Watch out for the spring!!
Like I've stated before, I wouldn't be surprised if Lympro will be able to distinguish between AD or other cognitive impairments/dementia's whether do to age, menopause or even PMS for that matter! All kidding aside, I hope this will be the cherry on top. One test using different algorithms to see what one really has going on upstairs.
"Of note, when we compared only the Alzheimer’s and cognitively intact groups, we had an accuracy of 90% in this small data set. In the upcoming Bridging Study, we will be comparing only Alzheimer’s and cognitively intact controls in order to give us a true clean measure of Version 1 vs. Version 2 using analytically strong data from BD. We believe this step will give us all the tools necessary to support the transition of the assay from BD into the target commercial CLIA lab partner and then restart the work PLS had conducted, and add other dementias into the cohort group (distinguishing Alzheimer’s from other dementias and cognitively intact controls using biomarkers such as Amyvid)."
"Some may ask, “How will you get another clinical study completed by the end of the year in the CLIA lab, as is required to support submission?” The answer is that we are proving right now that we can execute under such timelines with the current study. This is where the relationships and expertise and experiences of Dr. Kirby’s over 400 clinical trials are a huge advantage for Amarantus. We are establishing a well-oiled clinical organization capable of translating protocols to practice, and ultimately to data at a very rapid pace."
Watch out for the spring!!
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼